COMPASS Pathways (CMPS) Set to Announce Quarterly Earnings on Wednesday

COMPASS Pathways (NASDAQ:CMPS) is set to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.16). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

COMPASS Pathways Trading Up 1.4 %

COMPASS Pathways stock traded up $0.12 during trading on Monday, reaching $8.65. 66,573 shares of the company were exchanged, compared to its average volume of 660,576. COMPASS Pathways has a 52-week low of $5.01 and a 52-week high of $12.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.33 and a quick ratio of 13.33. The stock’s 50 day simple moving average is $9.51 and its two-hundred day simple moving average is $8.51. The company has a market capitalization of $535.78 million, a P/E ratio of -3.69 and a beta of 2.39.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of COMPASS Pathways in a research report on Friday, March 1st. Morgan Stanley initiated coverage on shares of COMPASS Pathways in a research note on Monday, April 1st. They issued an “overweight” rating and a $30.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Tuesday, April 30th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $47.40.

Insider Buying and Selling at COMPASS Pathways

In related news, Director George Jay Goldsmith sold 15,740 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $10.58, for a total value of $166,529.20. Following the completion of the transaction, the director now directly owns 4,079,107 shares of the company’s stock, valued at approximately $43,156,952.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Ekaterina Malievskaia sold 25,750 shares of COMPASS Pathways stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $8.65, for a total transaction of $222,737.50. Following the completion of the transaction, the insider now owns 4,036,154 shares of the company’s stock, valued at $34,912,732.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director George Jay Goldsmith sold 15,740 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $10.58, for a total transaction of $166,529.20. Following the completion of the transaction, the director now owns 4,079,107 shares in the company, valued at $43,156,952.06. The disclosure for this sale can be found here. Insiders have sold 140,601 shares of company stock valued at $1,338,911 in the last quarter. Corporate insiders own 4.25% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.